CA3136141A1 - Porcine circovirus type 3 (pcv3) vaccines, and production and uses thereof - Google Patents

Porcine circovirus type 3 (pcv3) vaccines, and production and uses thereof Download PDF

Info

Publication number
CA3136141A1
CA3136141A1 CA3136141A CA3136141A CA3136141A1 CA 3136141 A1 CA3136141 A1 CA 3136141A1 CA 3136141 A CA3136141 A CA 3136141A CA 3136141 A CA3136141 A CA 3136141A CA 3136141 A1 CA3136141 A1 CA 3136141A1
Authority
CA
Canada
Prior art keywords
composition
pcv3
protein
dose
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3136141A
Other languages
English (en)
French (fr)
Inventor
Arun Iyer
Luis Alejandro HERNANDEZ
Abby PATTERSON
Bailey Arruda
Luis Gabriel Gimenez-Lirola
David Michael Anstrom
Eric M. Vaughn
Pablo E. Pineyro Pineiro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Vetmedica GmbH
Iowa State University Research Foundation Inc ISURF
Original Assignee
Iowa State University Research Foundation Inc ISURF
Boehringer Ingelheim Animal Health USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iowa State University Research Foundation Inc ISURF, Boehringer Ingelheim Animal Health USA Inc filed Critical Iowa State University Research Foundation Inc ISURF
Publication of CA3136141A1 publication Critical patent/CA3136141A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3136141A 2019-04-04 2020-04-06 Porcine circovirus type 3 (pcv3) vaccines, and production and uses thereof Pending CA3136141A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962829400P 2019-04-04 2019-04-04
US62/829,400 2019-04-04
PCT/US2020/026930 WO2020206452A1 (en) 2019-04-04 2020-04-06 Porcine circovirus type 3 (pcv3) vaccines, and production and uses thereof

Publications (1)

Publication Number Publication Date
CA3136141A1 true CA3136141A1 (en) 2020-10-08

Family

ID=70680577

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3136141A Pending CA3136141A1 (en) 2019-04-04 2020-04-06 Porcine circovirus type 3 (pcv3) vaccines, and production and uses thereof

Country Status (13)

Country Link
US (4) US11701419B2 (https=)
EP (1) EP3953370A1 (https=)
JP (1) JP7762565B2 (https=)
KR (1) KR20220004967A (https=)
CN (1) CN114222579A (https=)
AU (2) AU2020256283B2 (https=)
BR (1) BR112021019859A2 (https=)
CA (1) CA3136141A1 (https=)
CL (1) CL2021002582A1 (https=)
MX (2) MX2021012051A (https=)
PH (1) PH12021552477A1 (https=)
WO (1) WO2020206452A1 (https=)
ZA (1) ZA202107428B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017066772A1 (en) 2015-10-16 2017-04-20 Kansas State University Research Foundation Porcine circovirus type 3 immunogenic compositions and methods of making and using the same
BR112021019859A2 (pt) * 2019-04-04 2022-02-15 Boehringer Ingelheim Animal Health Usa Inc Vacinas de circovírus suíno tipo 3 (pcv3) e produção e seus usos
CN115028688B (zh) * 2022-04-28 2024-04-16 山东信得科技股份有限公司 PCV3 Cap蛋白抗原肽、抗体及PCV3检测用免疫组化试剂盒
CN115960250B (zh) * 2022-08-06 2025-09-09 武汉科前生物股份有限公司 一种重组猪圆环病毒3型三聚体蛋白及其制备方法与应用
CN119019544B (zh) * 2024-08-09 2025-10-17 浙江理工大学 一种猪圆环病毒3型抗原检测试剂条及制备方法和应用
CN119307516A (zh) * 2024-11-15 2025-01-14 扬州大学 一种重组猪圆环病毒3型cap基因片段及其在双抗原夹心elisa抗体检测中的应用
CN119780429B (zh) * 2024-12-27 2025-12-26 华派生物技术(集团)股份有限公司 一种提高猪圆环病毒2型Cap蛋白抗原琼扩检测灵敏度的方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3479708A (en) 1968-05-15 1969-11-25 Edson P Foster Felting needle
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
AU7966987A (en) 1986-09-08 1988-04-07 Applied Biotechnology, Inc. Empty viral capsid vaccines
ES2026827A6 (es) 1991-03-26 1992-05-01 Ercros Sa Procedimiento para la produccion de una vacuna subunidad contra el parvovirus porcino.
JP3128133B2 (ja) 1991-06-06 2001-01-29 スティッチティング セントラール ディールゲネースクンディグ インスティトゥート 豚の奇病の原因体であるレリスタドエイジェント、それを含むワクチン組成物、豚の奇病の診断キット及び診断方法
DK0601062T4 (da) 1991-08-26 2001-03-14 Univ Minnesota SIRS-vaccine og diagnosefremgangsmåde
US6042830A (en) 1992-08-05 2000-03-28 Boehringer Ingelheim Vetmedica, Inc. Viral agent associated with mystery swine disease
AU2696792A (en) 1991-09-16 1993-04-27 David A Benfield Vaccine for mystery swine disease and method for diagnosis thereof
AU2684792A (en) 1991-10-14 1993-05-21 Akzo Nobel N.V. Porcine reproductive respiratory syndrome vaccine and diagnostic
DE69522984T2 (de) 1994-04-11 2002-04-25 Akzo Nobel Nv Europäische Vakzinstämme des Fortplanzungs-Atmungs-Syndromsvirus des Schweins
EP0732340B1 (en) 1995-03-14 2004-06-09 Akzo Nobel N.V. Expression of porcine reproductive respiratory syndrome virus polypeptides in the same cell
EP0835930B1 (en) 1996-10-09 2001-01-31 Akzo Nobel N.V. European vaccine strains of the porcine reproductive and respiratory syndrome virus (PRRSV)
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
CA2484604C (en) 2002-05-03 2011-08-02 Massachusetts Institute Of Technology .delta. 4,5 glycuronidase and uses thereof
PT2460817T (pt) 2004-12-30 2017-07-03 Boehringer Ingelheim Vetmedica Inc Composições imunogénicas de pcv2 e métodos de produção de tais composições
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
DK3766518T3 (da) 2005-12-29 2026-04-13 Boehringer Ingelheim Animal Health Usa Inc Immunogen pcv2-sammensætning til mindskelse af kliniske symptomer hos grise
PT2094872T (pt) 2006-12-15 2017-04-27 Boehringer Ingelheim Vetmedica Inc Tratamento de porcos seropositivos para o anticorpo anti-pcv2 com antigénio de pcv2
EP2215231A4 (en) 2007-10-15 2010-12-01 Univ Queensland EXPRESSION SYSTEM FOR MODULATING AN IMMUNE RESPONSE
WO2010098788A2 (en) * 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
CN103002911B (zh) * 2008-09-26 2015-08-26 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
HRP20151031T1 (hr) 2011-02-17 2015-11-06 Boehringer Ingelheim Vetmedica Gmbh Novi europski soj prrsv
CN104288760A (zh) 2013-07-18 2015-01-21 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
WO2017066772A1 (en) 2015-10-16 2017-04-20 Kansas State University Research Foundation Porcine circovirus type 3 immunogenic compositions and methods of making and using the same
MX381132B (es) 2016-11-03 2025-03-12 Boehringer Ingelheim Vetmedica Gmbh Vacuna contra parvovirus porcino.
CN108619503A (zh) 2017-03-24 2018-10-09 华南农业大学 一种猪圆环病毒基因工程亚单位疫苗及其制备方法与应用
CN108785667B (zh) 2017-04-28 2021-04-27 普莱柯生物工程股份有限公司 一种猪圆环病毒3型免疫原性组合物、制备方法和应用
CN109010818B (zh) * 2017-06-09 2021-11-09 普莱柯生物工程股份有限公司 一种预防和/或治疗猪圆环病毒感染的二联疫苗组合物及其制备方法和应用
CN109125719B (zh) 2017-06-19 2022-06-14 普莱柯生物工程股份有限公司 一种含猪圆环病毒3型、猪圆环病毒2型抗原的免疫原性组合物及其应用
CN109125720B (zh) * 2017-06-19 2021-11-09 普莱柯生物工程股份有限公司 一种含猪圆环病毒3型抗原的免疫原性组合物及其应用
CN108159409A (zh) * 2017-12-25 2018-06-15 南京大爻网络科技有限公司 一种猪圆环病毒3型Cap蛋白疫苗及其制备方法和应用
CN108359677A (zh) * 2018-02-01 2018-08-03 福建农林大学 提高猪圆环病毒2型和3型Cap蛋白串联表达效率的方法
JP7822127B2 (ja) * 2018-06-11 2026-03-02 セヴァ サンテ アニマレ ブタサーコウイルスに対するワクチン接種
CN109053896B (zh) * 2018-07-03 2021-08-17 青岛明勤生物科技有限公司 一种猪圆环病毒二价基因工程疫苗
CN108823231B (zh) 2018-07-09 2022-05-31 荣俊 一种猪圆环病毒3型基因工程亚单位疫苗及其制备方法
CN109207522B (zh) 2018-08-12 2022-05-27 扬州大学 表达猪圆环病毒3型截短Cap蛋白重组杆状病毒及其构建方法与引物
CN109207441B (zh) 2018-08-12 2022-05-27 扬州大学 重组杆状病毒表达猪圆环病毒3型Cap蛋白及其构建方法与引物
CN109550045B (zh) * 2018-12-26 2023-01-31 哈药集团生物疫苗有限公司 猪圆环病毒3型、猪细小病毒和猪流感三联灭活疫苗及其制备方法
CN109852622B (zh) 2019-01-18 2022-05-27 南京农业大学 一种可溶性PCV3Cap蛋白及其编码基因和应用
BR112021019859A2 (pt) * 2019-04-04 2022-02-15 Boehringer Ingelheim Animal Health Usa Inc Vacinas de circovírus suíno tipo 3 (pcv3) e produção e seus usos

Also Published As

Publication number Publication date
AU2025267386A1 (en) 2026-01-29
US11701419B2 (en) 2023-07-18
US20230302113A1 (en) 2023-09-28
US20210128712A1 (en) 2021-05-06
AU2020256283A1 (en) 2021-11-18
US20240226264A1 (en) 2024-07-11
US11896659B2 (en) 2024-02-13
MX2021012051A (es) 2022-01-18
CL2021002582A1 (es) 2022-07-22
US20260069672A1 (en) 2026-03-12
EP3953370A1 (en) 2022-02-16
MX2025004075A (es) 2025-06-02
BR112021019859A2 (pt) 2022-02-15
JP2022527627A (ja) 2022-06-02
CN114222579A (zh) 2022-03-22
AU2020256283A8 (en) 2024-01-11
ZA202107428B (en) 2023-12-20
PH12021552477A1 (en) 2022-07-18
JP7762565B2 (ja) 2025-10-30
US12433942B2 (en) 2025-10-07
AU2020256283B2 (en) 2025-08-14
WO2020206452A1 (en) 2020-10-08
KR20220004967A (ko) 2022-01-12

Similar Documents

Publication Publication Date Title
JP7445375B2 (ja) ブタサーコウイルス３型免疫原性組成物、その製造方法、およびその使用方法
CA3136141A1 (en) Porcine circovirus type 3 (pcv3) vaccines, and production and uses thereof
CN101610786B (zh) 预防和治疗亚临床pcvd
TWI479021B (zh) 第二型豬環狀病毒（ｐｃｖ２）免疫原組合物，及製備該組合物之方法
CN103562389A (zh) 用于有效表面展示抗原蛋白的新颖表达盒
TWI656213B (zh) 豬小病毒５ａ、用法及疫苗
TW201518506A (zh) 豬小病毒５ｂ、用法及疫苗
JP6072935B2 (ja) ブタパルボウイルス５ａ、使用方法およびワクチン
CN105263953B (zh) 猪细小病毒5a、使用方法及疫苗
RU2803427C1 (ru) Иммуногенные композиции для иммунизации свиней против цирковируса типа 3 и способы их получения и применения
KR20240028924A (ko) 높은 중화 항체를 유도하는 돼지 유행성 설사병 바이러스 및 불활화 백신 조성물
BR122024015306B1 (pt) Vetor compreendendo uma sequência de ácido nucleico que codifica uma proteína do circovírus suíno do tipo 3, célula hospedeira e composição compreendendo o mesmo

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240319

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250325

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250325

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250325

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250806

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20251208

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260324

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260324